All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The U.S. Department of Defense (DoD) is awarding Codagenix USD 4.4 million for further development of its next-generation tetravalent dengue vaccine candidate CodaVax-DENV.
